Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma

Bone Marrow Transplantation volume 53, pages 29–33 (2018)Cite this article

Subjects

Abstract

This study aimed to compare the real-life results of TECAM, a thiotepa-based conditioning regimen consisting of thiotepa (40 mg/m2 days −5 to −2), etoposide (200 mg/m2 days −6 to −3), cytarabine (200 mg/m2 days −4 to −1), cyclophosphamide (60 mg/kg day −3), and melphalan (60 mg/m2 days −2 to −1) with that of the conventional carmustine-based regimen BEAM. We reviewed 125 consecutive patients who underwent a first autologous transplantation (ASCT) for B-cell lymphomas at a large tertiary transplantation center between 1999 and 2014. TECAM (n=65) and BEAM (n=60) had comparable results (3yPFS 49 vs 62%, P=0.16; 3yOS 64 vs 71%, P=0.44; TRM 1.6 vs 5%, P=0.35) without a difference in toxicity or time to engraftment. Notably, comparable outcomes were observed even though patients treated with TECAM were older (55 vs 44) and had a trend towards more prior lines of therapy (>2 prior lines: 43 vs 27%, P=0.08). In this regard, 23% of TECAM patients were over the age of 65 yet could withstand therapy with similar results to younger patients. We conclude that, replacing carmustine by thiotepa and cyclophosphamide for ASCT conditioning, has comparable efficacy and safety profiles with a possible advantage in older patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  2. Majhail NS, Ness KK, Burns LJ, Sun C-L, Carter A, Francisco L et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant 2007; 13: 1153–1159.

    Article  Google Scholar 

  3. Jones JA, Qazilbash MH, Shih Y-CT, Cantor SB, Cooksley CD, Elting LS . In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer 2008; 112: 1096–1105.

    Article  Google Scholar 

  4. Chen Y-B, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21: 1046–1053.

    Article  Google Scholar 

  5. Fernandez HF, Escalón MP, Pereira D, Lazarus HM . Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 2007; 40: 505–513.

    Article  CAS  Google Scholar 

  6. Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458.

    Article  CAS  Google Scholar 

  7. Oliansky DM, Czuczman M, Fisher RI, Irwin FD, Lazarus HM, Omel J et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011; 17: 20–47.e30.

    Article  Google Scholar 

  8. Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 2013; 98: 765–770.

    Article  Google Scholar 

  9. Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant 2016; 51: 212–218.

    Article  CAS  Google Scholar 

  10. Nagler A, Berger R, Ackerstein A, Czyz JA, Diez-Martin JL, Naparstek E et al. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation. J Immunother 2010; 33: 326–333.

    Article  CAS  Google Scholar 

  11. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.

    Article  Google Scholar 

  12. Vittinghoff E, McCulloch CE . Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165: 710–718.

    Article  Google Scholar 

  13. Di Ianni M, Ballanti S, Iodice G, Reale A, Falzetti F, Minelli O et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin’s lymphoma. Hematology 2012; 17: 23–27.

    Article  CAS  Google Scholar 

  14. Falzetti F, Di Ianni M, Ballanti S, Iodice G, Reale A, Minelli O et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clin Exp Med 2012; 12: 165–171.

    Article  CAS  Google Scholar 

  15. Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M et al. Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL). Bone Marrow Transplant 2017; 52: 321–322.

    Article  CAS  Google Scholar 

  16. Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D et al. High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma 2008; 49: 1899–1906.

    Article  CAS  Google Scholar 

  17. Waheed F, Kancherla R, Seiter K, Liu D, Qureshi Z, Hoang A et al. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Leuk Lymphoma 2004; 45: 2253–2259.

    Article  CAS  Google Scholar 

  18. Bains T, Chen AI, Lemieux A, Hayes-Lattin BM, Leis JF, Dibb W et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2014; 55: 583–587.

    Article  CAS  Google Scholar 

  19. Isidori A, Christofides A, Visani G . Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma 2016; 57: 2499–2509.

    Article  CAS  Google Scholar 

  20. Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood 2014; 124: 3029–3031.

    Article  CAS  Google Scholar 

  21. Hermet E, Cabrespine A, Guièze R, Garnier A, Tempescul A, Lenain P et al. Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin’s lymphoma: a French Society of bone marrow transplantation and cellular therapy retrospective study. J Geriatr Oncol 2015; 6: 346–352.

    Article  CAS  Google Scholar 

  22. Sarid N, Joffe E, Gibstein L, Avivi I, Polliack A, Perry C et al. Reduced-dose ICE chemotherapy±rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2015; 8: 1–7.

    Google Scholar 

  23. Sánchez-Ortega I, Basak GW, Beohou E, van der Werf S, Labopin M, van Biezen A et al. Autologous hematopoietic cell transplantation in elderly patients aged 65 and older: a retrospective analysis by the complications and quality of life working party of the EBMT. Blood 2016; 128: 678.

    Google Scholar 

  24. Lahoud OB, Sauter CS, Hamlin PA, Dahi PB . High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma. Curr Oncol Rep 2015; 17: 42.

    Article  Google Scholar 

  25. Jantunen E, Canals C, Rambaldi A, Ossenkoppele G, Allione B, Blaise D et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008; 93: 1837–1842.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. E Joffe and D Rosenberg: These authors contributed equally to this work.

Authors and Affiliations

  1. Tel Aviv University Sackler School of Medicine, Tel-Aviv, Israel

    E Joffe, D Rosenberg, U Rozovski, C Perry, I Kirgner, S Trestman, O Gur, F Aviv, N Sarid, A Kolomansky, L Gepstein, Y Herishanu & E Naparstek

  2. Rabin Medical Center, Petah-Tikva, Israel

    E Joffe, D Rosenberg & U Rozovski

  3. Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel

    C Perry, I Kirgner, S Trestman, O Gur, F Aviv, N Sarid, A Kolomansky, L Gepstein, Y Herishanu & E Naparstek

Authors
  1. E Joffe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Rosenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U Rozovski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I Kirgner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Trestman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O Gur
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Aviv
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Sarid
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Kolomansky
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L Gepstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Y Herishanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E Naparstek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Joffe.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joffe, E., Rosenberg, D., Rozovski, U. et al. Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma. Bone Marrow Transplant 53, 29–33 (2018). https://doi.org/10.1038/bmt.2017.205

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.205

This article is cited by

Search

Advanced search

Quick links